Answers are grounded in this paper and cite their sources.
Case series reveals new eczematous eruption in IBD patients after stopping Janus kinase inhibitors, suggesting immune rebound effects.
Objectives: Janus kinase inhibitors (JAKi) are small-molecule therapies used in inflammatory bowel disease (IBD). We describe eight patients with IBD who developed an eczematous eruption, presumed atopic dermatitis (AD), after stopping JAKi therapy. Methods: This case series describes eight patients with IBD who developed de novo AD after withdrawal of JAKi therapy. Results: Median time to AD onset was 7 days (IQR 2-12). 2 cases with biopsy-confirmed AD resolved after reinitiation of JAKi therapy and adjunct AD treatments. Conclusions: A subset of IBD patients may have latent susceptibility to AD, unmasked by therapy cessation and potentially triggered by an immune rebound effect.
No takes yet. Share an insight, caveat, or question.
Yanofsky et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: